For the three months ended December 31st, 2018 vs December 31st, 2017, Advanced Micro Devices reported revenue of $1,419.00MM vs $1,340.00MM (up 5.90%) and analysts estimated basic earnings per share $0.04 vs -$0.01. For the twelve months ended December 31st, 2018 vs December 31st, 2017, Advanced Micro Devices reported revenue of $6,475.00MM vs $5,253.00MM (up 23.26%) and analysts estimated basic earnings per share $0.34 vs -$0.03. Analysts expect earnings to be released on April 24th, 2019. The report will be for the fiscal period ending March 31st, 2019. The reported EPS for the same quarter last year was $0.08. The estimated EPS forecast for the next fiscal year is $0.86 and is expected to report on February 4th, 2020.

For the twelve months ended December 31st, 2018 vs December 31st, 2017, Syros Pharmaceuticals reported revenue of $2.05MM vs $1.10MM (up 86.19%) and analysts estimated basic earnings per share -$1.91 vs -$2.13. Analysts expect earnings to be released on May 9th, 2019. The report will be for the fiscal period ending March 31st, 2019. Reported EPS for the same quarter last year was -$0.48. The estimated EPS forecast for the next fiscal year is -$2.13 and is expected to report on March 5th, 2020.

For the three months ended December 31st, 2018 vs December 31st, 2017, Integer reported revenue of $213.72MM vs $223.58MM (down 4.41%) and basic earnings per share $0.82 vs $1.73 (down 52.60%). For the twelve months ended December 31st, 2018 vs December 31st, 2017, Integer reported revenue of $1,215.01MM vs $1,136.08MM (up 6.95%) and analysts estimated basic earnings per share $5.23 vs $2.12 (up 146.70%). Analysts expect earnings to be released on May 2nd, 2019. The report will be for the fiscal period ending March 31st, 2019. The reported EPS for the same quarter last year was $0.61. The estimated EPS forecast for the next fiscal year is $4.77 and is expected to report on February 20th, 2020.

For the three months ended December 31st, 2018 vs December 31st, 2017, Mesoblast reported revenue of $1.87MM vs $13.40MM (down 86.04%) and analysts estimated basic earnings per share -$0.25 vs $0.15. For the twelve months ended June 30th, 2018 vs June 30th, 2017, Mesoblast reported revenue of $17.34MM vs $2.41MM (up 618.95%) and analysts estimated basic earnings per share -$0.38 vs -$0.96. Analysts expect earnings to be released on May 30th, 2019. The report will be for the fiscal period ending March 31st, 2019. The reported EPS for the same quarter last year was -$0.22. The estimated EPS forecast for the next fiscal year is -$0.94 and is expected to report on September 4th, 2019.

For the three months ended December 31st, 2018 vs December 31st, 2017, InnerWorkings reported revenue of $294.20MM vs $305.37MM (down 3.66%) and analysts estimated basic earnings per share -$0.55 vs -$0.01. For the twelve months ended December 31st, 2018 vs December 31st, 2017, InnerWorkings reported revenue of $1,121.55MM vs $1,138.36MM (down 1.48%) and analysts estimated basic earnings per share -$1.46 vs $0.31. Analysts expect earnings to be released on July 30th, 2019. The report will be for the fiscal period ending March 31st, 2019. The reported EPS for the same quarter last year was -$0.02. The estimated EPS forecast for the next fiscal year is $0.31 and is expected to report on March 3rd, 2020.

Market Source Research delivers the key research reports that helps serious investors, registered brokers, professional traders, and personal investment advisers find reliable information in today's markets. Market Source Research's team is comprised of financial professionals, many of which hold Chartered Financial Analyst® (CFA®) designations and FINRA® BrokerCheck® certifications. Whether identifying emerging trends, or discovering new opportunity, the team at Market Source Research is dedicated to providing accurate, informative, and objective content that's ahead of the curve. With insights on individual companies as well as sectors, readers get the industry's best available combination of big-picture perspective as well as granular detail.

Market Source Research's oversight and audit staff are registered analysts, brokers, and/or financial advisers ("Registered Members") working within Equity Research, Media, and Compliance departments. Market Source Research's roster includes qualified CFA® charterholders, licensed securities attorneys, and registered FINRA® members holding duly issued CRD® numbers. Current licensed status of several Registered Members at Market Source Research have been independently verified by an outside audit firm, including policy and audit records duly executed by Registered Members. Complaints, concerns, questions, or inquiries regarding this release should be directed to Market Source Research's Compliance department by Phone, at +1 (704) 343-6361, or by E-mail at [email protected].

Information contained herein is not an offer or solicitation to buy, hold, or sell any security. Market Source Research, Market Source Research members, and/or Market Source Research affiliates are not responsible for any gains or losses that result from the opinions expressed. Market Source Research makes no representations as to the completeness, accuracy, or timeliness of the material provided and all materials are subject to change without notice. Market Source Research has not been compensated for the publication of this press release by any of the above mentioned companies. Market Source Research is not a financial advisory firm, investment adviser, or broker-dealer, and does not undertake any activities that would require such registration. For our full disclaimer, disclosure, and terms of service please visit our website.